Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/2162402X.2017.1315486 http://scihub22266oqcxt.onion/10.1080/2162402X.2017.1315486 C5665084!5665084!29123948     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Oncoimmunology 2017 ; 6 (10): ä Nephropedia Template TP {{tp|p=29123948|t=2017. No patient left behind: The promise of immune priming with epigenetic agents |pdf=|usr=}}{{29123948}} gab.com Text No patient left behind: The promise of immune priming with epigenetic agents JO: Oncoimmunology http://www.kidney.de/pget.php?&tw=1&pmid=29123948 #FOAvip Checkpoint inhibitors, monoclonal antibodies that inhibit PD-1 or CTLA-4, have revolutionized the treatment of multiple cancers. Despite the enthusiasm for the clinical successes of checkpoint inhibitors, and immunotherapy, in general, only a minority of patients with specific tumor types actually benefit from treatment. Emerging evidence implicates epigenetic alterations as a mechanism of clinical resistance to immunotherapy. This review presents evidence for that association, summarizes the epi-based mechanisms by which tumors evade immunogenic cell death, discusses epigenetic modulation as a component of an integrated strategy to boost anticancer T cell effector function in relation to a tumor immunosuppression cycle and, finally, makes the case that the success of this no-patient-left-behind strategy critically depends on the toxicity profile of the epigenetic agent(s). Twit Text FOAVip No patient left behind: The promise of immune priming with epigenetic agents ????Oncoimmunology http://www.kidney.de/pget.php?&tw=1&pmid=29123948 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29123948 #FOAvip English Wikipedia <ref>{{Cite pmid|29123948}}</ref> No patient left behind: The promise of immune priming with epigenetic agents #MMPMID29123948 Carter CA; Oronsky BT; Roswarski J; Oronsky AL; Oronsky N; Scicinski J; Lybeck H; Kim MM; Lybeck M; Reid TR Oncoimmunology 2017[]; 6 (10): ä PMID29123948show ga Checkpoint inhibitors, monoclonal antibodies that inhibit PD-1 or CTLA-4, have revolutionized the treatment of multiple cancers. Despite the enthusiasm for the clinical successes of checkpoint inhibitors, and immunotherapy, in general, only a minority of patients with specific tumor types actually benefit from treatment. Emerging evidence implicates epigenetic alterations as a mechanism of clinical resistance to immunotherapy. This review presents evidence for that association, summarizes the epi-based mechanisms by which tumors evade immunogenic cell death, discusses epigenetic modulation as a component of an integrated strategy to boost anticancer T cell effector function in relation to a tumor immunosuppression cycle and, finally, makes the case that the success of this no-patient-left-behind strategy critically depends on the toxicity profile of the epigenetic agent(s). äNo patient left behind: The promise of immune priming with epigenetic (epmc).pdf DeepDyve Pubget Overpricing